Limits...
Efficiency and safety of subconjunctival injection of anti-VEGF agent - bevacizumab - in treating dry eye.

Jiang X, Lv H, Qiu W, Liu Z, Li X, Wang W - Drug Des Devel Ther (2015)

Bottom Line: Dry eye is a chronic inflammatory ocular surface disease with high prevalence.There was no visual and systemic threat observed in any patient.Subconjunctival injection of 100 μL 25 mg/mL bevacizumab is a safe and efficient treatment for ocular surface inflammation of dry eye disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Peking University Third Hospital, Beijing, People's Republic of China.

ABSTRACT

Purpose: Dry eye is a chronic inflammatory ocular surface disease with high prevalence. The current therapies for dry eye remain to be unspecific and notcomprehensive. This study aims to explore safety and efficacy of a novel treatment - subconjunctival injection of bevacizumab - in dry eye patients.

Methods: Sixty-four eyes of 32 dry eye patients received subconjunctival injection of 100 μL 25 mg/mL bevacizumab. Dry eye symptoms, signs (corrected visual acuity, intraocular pressure, conjunctival vascularity, corneal staining, tear break-up time, Marx line score, and blood pressure), and conjunctival impression cytology were evaluated 3 days before and 1 week, 1 month, and 3 months after injection.

Results: Significant improvements were observed in dry eye symptoms, tear break-up time, and conjunctival vascularization area at all the visits after injection compared to the baseline (P<0.05). The density of the goblet cell increased significantly at 1 month and 3 months after injection (P<0.05). There was no visual and systemic threat observed in any patient.

Conclusion: Subconjunctival injection of 100 μL 25 mg/mL bevacizumab is a safe and efficient treatment for ocular surface inflammation of dry eye disease.

No MeSH data available.


Related in: MedlinePlus

Conjunctival cytology analysis (stained with periodic acid–Schiff, 40×).Notes: (A) refers to the staining before injection. (B) represents the staining 1 month after injection. (C) is the staining 3 months after injection. Compared to (A), the epithelial in (B) and (C) is more regular, rounder and smaller, the cell gap in (B) and (C) is much closer. The density of goblet cell, is much higher in (B) and (C), compared to (A).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4472070&req=5

f2-dddt-9-3043: Conjunctival cytology analysis (stained with periodic acid–Schiff, 40×).Notes: (A) refers to the staining before injection. (B) represents the staining 1 month after injection. (C) is the staining 3 months after injection. Compared to (A), the epithelial in (B) and (C) is more regular, rounder and smaller, the cell gap in (B) and (C) is much closer. The density of goblet cell, is much higher in (B) and (C), compared to (A).

Mentions: After ImageJ analysis of the percentage of bulbar conjunctival vascularization (Figure 1), a significant decrease was observed at 1 week, 1 month, and 3 months after injection compared to that of the baseline (P<0.01). In the light of conjunctival cytology impression analysis (Figure 2), the goblet cell density was significantly increased at 1 month and 3 months after injection compared to that of the baseline (P<0.05) (Table 2).


Efficiency and safety of subconjunctival injection of anti-VEGF agent - bevacizumab - in treating dry eye.

Jiang X, Lv H, Qiu W, Liu Z, Li X, Wang W - Drug Des Devel Ther (2015)

Conjunctival cytology analysis (stained with periodic acid–Schiff, 40×).Notes: (A) refers to the staining before injection. (B) represents the staining 1 month after injection. (C) is the staining 3 months after injection. Compared to (A), the epithelial in (B) and (C) is more regular, rounder and smaller, the cell gap in (B) and (C) is much closer. The density of goblet cell, is much higher in (B) and (C), compared to (A).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4472070&req=5

f2-dddt-9-3043: Conjunctival cytology analysis (stained with periodic acid–Schiff, 40×).Notes: (A) refers to the staining before injection. (B) represents the staining 1 month after injection. (C) is the staining 3 months after injection. Compared to (A), the epithelial in (B) and (C) is more regular, rounder and smaller, the cell gap in (B) and (C) is much closer. The density of goblet cell, is much higher in (B) and (C), compared to (A).
Mentions: After ImageJ analysis of the percentage of bulbar conjunctival vascularization (Figure 1), a significant decrease was observed at 1 week, 1 month, and 3 months after injection compared to that of the baseline (P<0.01). In the light of conjunctival cytology impression analysis (Figure 2), the goblet cell density was significantly increased at 1 month and 3 months after injection compared to that of the baseline (P<0.05) (Table 2).

Bottom Line: Dry eye is a chronic inflammatory ocular surface disease with high prevalence.There was no visual and systemic threat observed in any patient.Subconjunctival injection of 100 μL 25 mg/mL bevacizumab is a safe and efficient treatment for ocular surface inflammation of dry eye disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Peking University Third Hospital, Beijing, People's Republic of China.

ABSTRACT

Purpose: Dry eye is a chronic inflammatory ocular surface disease with high prevalence. The current therapies for dry eye remain to be unspecific and notcomprehensive. This study aims to explore safety and efficacy of a novel treatment - subconjunctival injection of bevacizumab - in dry eye patients.

Methods: Sixty-four eyes of 32 dry eye patients received subconjunctival injection of 100 μL 25 mg/mL bevacizumab. Dry eye symptoms, signs (corrected visual acuity, intraocular pressure, conjunctival vascularity, corneal staining, tear break-up time, Marx line score, and blood pressure), and conjunctival impression cytology were evaluated 3 days before and 1 week, 1 month, and 3 months after injection.

Results: Significant improvements were observed in dry eye symptoms, tear break-up time, and conjunctival vascularization area at all the visits after injection compared to the baseline (P<0.05). The density of the goblet cell increased significantly at 1 month and 3 months after injection (P<0.05). There was no visual and systemic threat observed in any patient.

Conclusion: Subconjunctival injection of 100 μL 25 mg/mL bevacizumab is a safe and efficient treatment for ocular surface inflammation of dry eye disease.

No MeSH data available.


Related in: MedlinePlus